Is Abilify (aripiprazole) a Schedule II controlled substance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Abilify a Schedule 2 Drug?

No, Abilify (aripiprazole) is not a controlled substance at all—it is not classified under any DEA schedule (Schedule I through V). 1

Controlled Substance Classification

  • Aripiprazole has no DEA scheduling because it is not considered a controlled substance by the Drug Enforcement Administration. 1

  • The FDA explicitly states in the drug label that "Aripiprazole is not a controlled substance." 1

  • This means aripiprazole can be prescribed without the restrictions that apply to Schedule II drugs (like oxycodone, morphine, or amphetamines) or even Schedule III-V substances. 1

Abuse and Dependence Potential

  • Aripiprazole has not been systematically studied for abuse potential, tolerance, or physical dependence in humans, though the FDA recommends evaluating patients for drug abuse history and monitoring for signs of misuse. 1

  • In animal studies with monkeys, withdrawal symptoms were observed upon abrupt cessation, but clinical trials did not reveal drug-seeking behavior—though these observations were not systematic. 1

  • The unique pharmacology of aripiprazole as a partial dopamine D2 agonist (rather than a full antagonist like most antipsychotics) may contribute to its lower abuse liability compared to substances that produce more pronounced dopaminergic effects. 2

Clinical Context

  • While aripiprazole is not a controlled substance, patients should still be monitored for signs of misuse or abuse (e.g., tolerance development, dose escalation, drug-seeking behavior), particularly in those with substance use disorder history. 1

  • Some research has explored aripiprazole's potential role in treating substance dependence disorders (alcohol, cocaine, amphetamine, nicotine) due to its dopaminergic modulation, though evidence remains limited. 3

Common Confusion

A common pitfall is confusing aripiprazole's lack of controlled substance status with the need for careful prescribing. While it requires no special DEA prescribing requirements, gradual tapering is still recommended when discontinuing to avoid withdrawal symptoms like anxiety, insomnia, irritability, and mood changes. 4

References

Research

Aripiprazole, alcohol and substance abuse: a review.

European review for medical and pharmacological sciences, 2012

Guideline

Aripiprazole Dose Reduction Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.